Janux Therapeutics, Inc.
NASDAQ:JANXBiotechnology
-$0.25 today
- Market cap
- $630.80M
- Beta
- 2.52
- P/E (TTM)
- -7.6
- EPS (TTM)
- -$1.83
Volume 0.98M
Average 1.02M
JANX Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Janux Therapeutics, Inc.NASDAQ: JANX
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $3.55M rose 539.9% year over year, ahead of the -98.0% change in trailing-twelve-month financing cash flow. Sequentially, it rose 20.4% from the prior quarter. Over 3 fiscal years it compounded at +114.7% a year.
Context
- Financing cash flow amounted to 49.5% of revenue in FY2025, down 6686.8 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +539.9% holds above the trailing-twelve-month pace of -98.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 4.95M USD
- Year-over-year change
- -99.3%
- 4-year CAGR
- -66.4%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.95M | -99.3% |
| FY2024 | 2024-12-31 | 713.24M | +1097.7% |
| FY2023 | 2023-12-31 | 59.55M | +11809.6% |
| FY2022 | 2022-12-31 | 500K | -99.9% |
| FY2021 | 2021-12-31 | 386.52M | — |
Financing Cash Flow vs competitors
How JANX compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -98.0% is the 9th highest of 10, against a peer median of +4594.2%.
- Financing cash flow amounts to 36.7% of revenue for JANX, versus a peer median of 210.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $436.09M USD | +91.6% | +2614.9% | — | |
| LTM Mar 2026 | $344.93M USD | +4594.2% | +454.4% | 970.5% | |
| LTM Sep 2026 | $327.45M USD | +22878.8% | -16.3% | 292364.3% | |
| LTM Mar 2026 | $133.79M USD | +14802.1% | +19.6% | — | |
| LTM Mar 2026 | €118.48M EUR | -17.9% | -8.9% | 317.7% | |
| LTM Sep 2026 | $115.15M USD | +822385.3% | — | 8.5% | |
| LTM Mar 2026 | $103.05M USD | +5.6% | -90.3% | 103.5% | |
| LTM Mar 2026 | $69.59M USD | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $7.94M USD | -98.0% | +114.7% | 36.7% | |
| LTM Mar 2026 | $1.47M USD | -99.4% | — | — | |
VRXAVeraxa Biotech Holding AG | — | — | — | — | — |
| Peer median (excluding JANX) | — | +4594.2% | +19.6% | 210.6% | |
Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (32.67M) | (63.06M) | (58.29M) | (68.99M) | (113.63M) |
| Depreciation & Amortization | 113K | 841K | 1.96M | 2.06M | 2.03M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 6.91M | 17.2M | 20.01M | 33.02M | 40.22M |
| Change in Working Capital | 8.84M | 4.28M | (6.55M) | 685K | 6.71M |
| Accounts Receivables | 8M | 0 | 0 | 0 | 0 |
| Inventory | 831K | 0 | 0 | 0 | 0 |
| Accounts Payables | 2.14M | (294K) | 277K | 1.58M | 977K |
| Other Working Capital | (2.13M) | 4.57M | (6.83M) | (899K) | 5.74M |
| Other Non-Cash Items | (169K) | (2.18M) | (7.69M) | (10.59M) | (17.57M) |
| Operating Cash Flow | (16.98M) | (42.92M) | (50.58M) | (43.81M) | (82.24M) |
| Capital Expenditures | (1.48M) | (6.45M) | (1.85M) | (359K) | (1.04M) |
| Acquisitions (Net) | 339.48M | (64.71M) | 0 | 0 | 0 |
| Purchases of Investments | (473.63M) | (294.39M) | (317.34M) | (470.58M) | (705.22M) |
| Sales of Investments | 134.15M | 359.1M | 278M | 212.92M | 405.28M |
| Other Investing Activities | (339.48M) | 64.71M | 0 | 0 | 0 |
| Investing Cash Flow | (340.96M) | 58.27M | (41.19M) | (258.02M) | (300.98M) |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 204.17M | 500K | 56.53M | 698.27M | 5.29M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (347K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 1.81M | 0 | 3.02M | 14.97M | 0 |
| Financing Cash Flow | 386.52M | 500K | 59.55M | 713.24M | 4.95M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 28.59M | 15.84M | (32.22M) | 411.4M | (378.27M) |
| Free Cash Flow | (18.46M) | (49.37M) | (52.43M) | (44.17M) | (83.28M) |
Janux Therapeutics, Inc.
NASDAQ:JANX
Intrinsic Alpha fair value
Locked
Current Price
$10.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.